Biogen Bolsters Position In MS Now That Tecfidera Is A Blockbuster
This article was originally published in The Pink Sheet Daily
The spec pharma’s latest MS offering surpasses $1 billion in sales as roll-out begins in Europe and focuses some of its resources toward its budding hemophilia franchise.
You may also be interested in...
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.
Biogen Idec announced Feb.6 that it will pay $3.25 billion to its partner Elan for full rights to the multiple sclerosis drug Tysabri. The deal was not a surprise to Biogen investors, but it leaves Elan with a war chest of cash and virtually no commercial assets.